Free tool
FAERS Monitor: Opill
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017031 or its brand name (Opill, Norgestrel). Reports on generic versions are filed under their own applications.
Reports
1,356
Serious
302
22% of reports
Hospitalization
23
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- heavy menstrual bleeding245
- pregnancy on oral contraceptive206
- intermenstrual bleeding182
- polymenorrhoea155
- product dose omission issue79
- nausea77
- adverse drug reaction68
- headache66
- weight increased63
- acne53
- dysmenorrhoea52
- menstruation irregular51
- product use in unapproved indication47
- muscle spasms40
- vaginal haemorrhage40
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2008 | 1 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 349 |
| 2025 | 937 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,803 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pregnancy on oral contraceptiveSignal | 206 | 1322.7 | 1159.2 | 249,520 |
| polymenorrhoeaSignal | 155 | 725.7 | 623.4 | 106,493 |
| intermenstrual bleedingSignal | 182 | 522.1 | 454.9 | 91,102 |
| heavy menstrual bleedingSignal | 245 | 434.2 | 386.9 | 102,625 |
| dysmenorrhoeaSignal | 52 | 61.1 | 46.8 | 3,003 |
| menstruation irregularSignal | 51 | 29.6 | 22.6 | 1,379 |
| vaginal haemorrhageSignal | 40 | 14.3 | 10.5 | 482 |
| adverse drug reactionSignal | 68 | 11.8 | 9.3 | 660 |
| acneSignal | 53 | 10.8 | 8.3 | 465 |
| weight increasedSignal | 63 | 4.4 | 3.4 | 162 |
| product dose omission issueSignal | 79 | 4.2 | 3.4 | 190 |
| muscle spasmsSignal | 40 | 3.4 | 2.5 | 65 |
| product use in unapproved indicationSignal | 47 | 2.9 | 2.2 | 59 |
| headache | 66 | 1.6 | 1.3 | 16 |
| nausea | 77 | 1.5 | 1.2 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.